Growth Hormone Therapy in GH-deficient Adults: Continuous vs. Alternate-days Treatment

C. Giavoli, V. Cappiello, S. Porretti, C. L. Ronchi, E. Orsi, P. Beck-Peccoz, M. Arosio

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In the present report, we have compared 12 months of rhGH therapy given daily (D) at the beginning and then on alternate days (A) to 20 subjects with severe adult-onset GH deficiency (GHD). Aim of the study was to establish whether the lower frequency injection regimen is as effective as the daily dose. Measurements included: IGF-I levels, body composition (BF%), lipid profile, insulin sensitivity by homeostasis model assessment (HOMA-IR) and quantitative insulin check index (QUICKI), as well as thyroid function. Evaluation on A therapy was performed both 12 and 36 hours after the last rhGH injection. The final rhGH dose was 0.3 ± 0.1 mg/day. During A, the dose used in D was doubled and given on alternate days. Recombinant hGH given during the A period induced changes in IGF-I levels, BF% and lipid profile comparable to daily treatment. HOMA-IR increased similarly after both regimens, though QUICKI did not significantly change. A significant reduction in serum FT4 levels occurred after both D and A therapy, so that an adjustment of L-T4 replacement dose in 5 of 20 patients was necessary. No differences were found in the various parameters after 12 and 36 hours post rhGH injection. In conclusion, rhGH therapy given on alternate days is clinically effective and may result in improved patient compliance. Monitoring glucose tolerance and thyroid function while on rhGH is essential.

Original languageEnglish
Pages (from-to)557-561
Number of pages5
JournalHormone and Metabolic Research
Volume35
Issue number9
DOIs
Publication statusPublished - Sep 1 2003

Fingerprint

Growth Hormone
Insulin
Insulin-Like Growth Factor I
Lipids
Injections
Thyroid Gland
Therapeutics
Social Adjustment
Glucose
Patient Compliance
Body Composition
Monitoring
Insulin Resistance
Chemical analysis
Homeostasis
Serum
Compliance

Keywords

  • GH Deficiency
  • GH Replacement
  • IGF-I
  • Insulin Resistance

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Growth Hormone Therapy in GH-deficient Adults : Continuous vs. Alternate-days Treatment. / Giavoli, C.; Cappiello, V.; Porretti, S.; Ronchi, C. L.; Orsi, E.; Beck-Peccoz, P.; Arosio, M.

In: Hormone and Metabolic Research, Vol. 35, No. 9, 01.09.2003, p. 557-561.

Research output: Contribution to journalArticle

Giavoli, C. ; Cappiello, V. ; Porretti, S. ; Ronchi, C. L. ; Orsi, E. ; Beck-Peccoz, P. ; Arosio, M. / Growth Hormone Therapy in GH-deficient Adults : Continuous vs. Alternate-days Treatment. In: Hormone and Metabolic Research. 2003 ; Vol. 35, No. 9. pp. 557-561.
@article{7b5a1f058b3f45ba9316f4ecd1762b7b,
title = "Growth Hormone Therapy in GH-deficient Adults: Continuous vs. Alternate-days Treatment",
abstract = "In the present report, we have compared 12 months of rhGH therapy given daily (D) at the beginning and then on alternate days (A) to 20 subjects with severe adult-onset GH deficiency (GHD). Aim of the study was to establish whether the lower frequency injection regimen is as effective as the daily dose. Measurements included: IGF-I levels, body composition (BF{\%}), lipid profile, insulin sensitivity by homeostasis model assessment (HOMA-IR) and quantitative insulin check index (QUICKI), as well as thyroid function. Evaluation on A therapy was performed both 12 and 36 hours after the last rhGH injection. The final rhGH dose was 0.3 ± 0.1 mg/day. During A, the dose used in D was doubled and given on alternate days. Recombinant hGH given during the A period induced changes in IGF-I levels, BF{\%} and lipid profile comparable to daily treatment. HOMA-IR increased similarly after both regimens, though QUICKI did not significantly change. A significant reduction in serum FT4 levels occurred after both D and A therapy, so that an adjustment of L-T4 replacement dose in 5 of 20 patients was necessary. No differences were found in the various parameters after 12 and 36 hours post rhGH injection. In conclusion, rhGH therapy given on alternate days is clinically effective and may result in improved patient compliance. Monitoring glucose tolerance and thyroid function while on rhGH is essential.",
keywords = "GH Deficiency, GH Replacement, IGF-I, Insulin Resistance",
author = "C. Giavoli and V. Cappiello and S. Porretti and Ronchi, {C. L.} and E. Orsi and P. Beck-Peccoz and M. Arosio",
year = "2003",
month = "9",
day = "1",
doi = "10.1055/s-2003-42659",
language = "English",
volume = "35",
pages = "557--561",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "9",

}

TY - JOUR

T1 - Growth Hormone Therapy in GH-deficient Adults

T2 - Continuous vs. Alternate-days Treatment

AU - Giavoli, C.

AU - Cappiello, V.

AU - Porretti, S.

AU - Ronchi, C. L.

AU - Orsi, E.

AU - Beck-Peccoz, P.

AU - Arosio, M.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - In the present report, we have compared 12 months of rhGH therapy given daily (D) at the beginning and then on alternate days (A) to 20 subjects with severe adult-onset GH deficiency (GHD). Aim of the study was to establish whether the lower frequency injection regimen is as effective as the daily dose. Measurements included: IGF-I levels, body composition (BF%), lipid profile, insulin sensitivity by homeostasis model assessment (HOMA-IR) and quantitative insulin check index (QUICKI), as well as thyroid function. Evaluation on A therapy was performed both 12 and 36 hours after the last rhGH injection. The final rhGH dose was 0.3 ± 0.1 mg/day. During A, the dose used in D was doubled and given on alternate days. Recombinant hGH given during the A period induced changes in IGF-I levels, BF% and lipid profile comparable to daily treatment. HOMA-IR increased similarly after both regimens, though QUICKI did not significantly change. A significant reduction in serum FT4 levels occurred after both D and A therapy, so that an adjustment of L-T4 replacement dose in 5 of 20 patients was necessary. No differences were found in the various parameters after 12 and 36 hours post rhGH injection. In conclusion, rhGH therapy given on alternate days is clinically effective and may result in improved patient compliance. Monitoring glucose tolerance and thyroid function while on rhGH is essential.

AB - In the present report, we have compared 12 months of rhGH therapy given daily (D) at the beginning and then on alternate days (A) to 20 subjects with severe adult-onset GH deficiency (GHD). Aim of the study was to establish whether the lower frequency injection regimen is as effective as the daily dose. Measurements included: IGF-I levels, body composition (BF%), lipid profile, insulin sensitivity by homeostasis model assessment (HOMA-IR) and quantitative insulin check index (QUICKI), as well as thyroid function. Evaluation on A therapy was performed both 12 and 36 hours after the last rhGH injection. The final rhGH dose was 0.3 ± 0.1 mg/day. During A, the dose used in D was doubled and given on alternate days. Recombinant hGH given during the A period induced changes in IGF-I levels, BF% and lipid profile comparable to daily treatment. HOMA-IR increased similarly after both regimens, though QUICKI did not significantly change. A significant reduction in serum FT4 levels occurred after both D and A therapy, so that an adjustment of L-T4 replacement dose in 5 of 20 patients was necessary. No differences were found in the various parameters after 12 and 36 hours post rhGH injection. In conclusion, rhGH therapy given on alternate days is clinically effective and may result in improved patient compliance. Monitoring glucose tolerance and thyroid function while on rhGH is essential.

KW - GH Deficiency

KW - GH Replacement

KW - IGF-I

KW - Insulin Resistance

UR - http://www.scopus.com/inward/record.url?scp=0141991083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141991083&partnerID=8YFLogxK

U2 - 10.1055/s-2003-42659

DO - 10.1055/s-2003-42659

M3 - Article

C2 - 14517774

AN - SCOPUS:0141991083

VL - 35

SP - 557

EP - 561

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 9

ER -